Carl Zeiss Meditec AG (XBUL:AFX) FFO


XBUL:AFX Carl Zeiss Meditec AG XBUL:AFX
68 GF Score
Price лв42.34
GF Value лв101.24
! 3 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG FFO?

FFO (Funds from operations) only applies to REITs.

XBUL:AFX
68GF Score
Carl Zeiss Meditec AG XBUL:AFX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Carl Zeiss Meditec AG (XBUL:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of лв42.34 is trading 58.2% below its estimated GF Value™ of лв101.24.

Key valuation signals for XBUL:AFX:

  • FFO:
  • GF Value™: лв101.24 vs. price of лв42.34 (58.2% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the XBUL:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
68GF Score

Get the complete analysis for XBUL:AFX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

лв42.34
Price
лв101.24
GF Value